Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...

Regeneron acquires 23andMe for $256M following bankruptcy auction Regeneron will take over key assets including 23andMe’s Personal Genome Service, Biobank, Total Health, and research operations, ...

Regeneron Pharmaceuticals on Monday announced it will acquire "substantially all" of 23andMe's assets for $256 million. Stream NBC4 newscasts for free right here, right now.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...

Regeneron to acquire bankrupt 23andMe for $256M, aiming to leverage genetic data for drug development while maintaining consumer genomics services.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy.